Zacks Research Comments on Qiagen’s Q4 Earnings (NYSE:QGEN)

Qiagen N.V. (NYSE:QGEN) – Stock analysts at Zacks Research dropped their Q4 2025 earnings per share estimates for shares of Qiagen in a research note issued on Thursday, January 22nd. Zacks Research analyst Team now forecasts that the company will post earnings of $0.62 per share for the quarter, down from their previous estimate of $0.62. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q3 2026 earnings at $0.67 EPS, Q4 2026 earnings at $0.63 EPS, Q1 2027 earnings at $0.68 EPS, Q2 2027 earnings at $0.70 EPS and Q3 2027 earnings at $0.72 EPS.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The company had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. During the same period last year, the company earned $0.60 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year.

Other analysts also recently issued research reports about the stock. Barclays reaffirmed an “overweight” rating and set a $57.89 price target (up previously from $55.79) on shares of Qiagen in a report on Monday, December 15th. UBS Group reissued a “neutral” rating on shares of Qiagen in a report on Wednesday. Deutsche Bank Aktiengesellschaft downgraded shares of Qiagen from a “buy” rating to a “hold” rating and boosted their target price for the stock from $52.00 to $54.00 in a report on Thursday. Citigroup lowered Qiagen from a “buy” rating to a “neutral” rating and dropped their price target for the company from $57.89 to $52.63 in a research note on Thursday, December 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Qiagen currently has a consensus rating of “Hold” and a consensus price target of $53.04.

Qiagen Stock Up 2.4%

Qiagen stock opened at $55.56 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. The firm has a 50 day moving average price of $48.88 and a two-hundred day moving average price of $49.52. Qiagen has a 52-week low of $39.61 and a 52-week high of $57.81. The firm has a market cap of $11.73 billion, a price-to-earnings ratio of 28.68, a PEG ratio of 2.61 and a beta of 0.66.

Institutional Trading of Qiagen

Several hedge funds have recently modified their holdings of the company. Danske Bank A S purchased a new position in shares of Qiagen in the 3rd quarter worth approximately $36,000. Smartleaf Asset Management LLC boosted its stake in Qiagen by 1,383.3% in the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after acquiring an additional 830 shares in the last quarter. MAI Capital Management grew its holdings in Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after purchasing an additional 889 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Qiagen by 400.5% in the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after purchasing an additional 849 shares during the last quarter. Finally, Allworth Financial LP increased its position in shares of Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after purchasing an additional 796 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Zacks Research nudged its Q1 2027 EPS estimate up to $0.68 from $0.67, a small positive signal for near‑term earnings expectations that may be helping support the stock.
• Neutral Sentiment: Media pieces note that analysts are “conflicted” on Qiagen, highlighting mixed buy/hold/sell views rather than a consensus directional change; this increases focus and trading but doesn’t force a clear fundamental shift. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: A similar roundup notes mixed analyst views again (adds visibility and trading interest but not a unified directional signal). Analysts Conflicted on These Healthcare Names
• Negative Sentiment: Zacks Research lowered multiple quarterly EPS estimates (including Q3 2027 and Q4 2026) and trimmed near‑term forecasts overall — a signal that analysts see some softening in near‑term profit trends. Consensus full‑year EPS remains around $2.26, but the downward quarterly revisions are a near‑term negative for sentiment.
• Negative Sentiment: Deutsche Bank downgraded Qiagen, a direct negative from a major sell‑side firm that can pressure sentiment and weighing on shares despite the mixed analyst picture. Deutsche Bank downgrades Qiagen NV (QGEN)

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.